Ken Griffin Essa Pharma Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.45 - $7.1 $17,355 - $27,690	-3,900 Reduced 84.78%	700 $4,000
Q2 2024 Aug 14, 2024	SELL	$4.63 - $8.42 $7,871 - $14,314	-1,700 Reduced 26.98%	4,600 $24,000
Q1 2024 May 15, 2024	SELL	$6.17 - $10.65 $3,702 - $6,390	-600 Reduced 8.7%	6,300 $53,000
Q4 2023 Feb 14, 2024	SELL	$2.74 - $7.35 $4,658 - $12,495	-1,700 Reduced 19.77%	6,900 $45,000
Q3 2023 Nov 14, 2023	BUY	$2.65 - $3.31 $11,395 - $14,233	4,300 Added 100.0%	8,600 $26,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.34 $26,520 - $34,068	-10,200 Reduced 70.34%	4,300 $11,000
Q1 2023 May 15, 2023	SELL	$2.56 - $3.55 $24,064 - $33,370	-9,400 Reduced 39.33%	14,500 $43,000
Q4 2022 Feb 14, 2023	SELL	$1.5 - $4.82 $22,650 - $72,782	-15,100 Reduced 38.72%	23,900 $60,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.44 $38,325 - $75,336	21,900 Added 128.07%	39,000 $71,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $71M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.